



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/011,940	03/03/99	NAUCK	8648610SWD

HM22/0601

MERCHANT GOULD SMITH EDELL
WELTER & SCHMIDT
3100 NORWEST CENTER
90 SOUTH SEVENTH STREET
MINNEAPOLIS MN 55402-4131

EXAMINER

CELSA, B

ART UNIT

PAPER NUMBER

1627

DATE MAILED:

06/01/00

14

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

file copy

Office Action Summary

Application No.

09/011,940

Applicant(s)

Nauck et al.

Examiner

Bennett Celsa

Group Art Unit

1627



☐ Responsive to communication(s) filed on _____

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire three month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

☒ Claim(s) 1, 2, 17-26, and 28-50 is/are pending in the application.

Of the above, claim(s) 26, 28-31, and 36-39 is/are withdrawn from consideration.

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 1, 2, 17-25, 32-35, and 40-50 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☐ Claims _____ are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) _____

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☒ Notice of References Cited, PTO-892

☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). 7, 13

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1627

DETAILED ACTION

Status of the Claims

Claims 1-2, 17-26 and 28-50 are currently pending.

Claims 26, 28-31 and 36-39 are withdrawn from consideration as being directed to a nonelected invention.

Claims 1-2, 17-25, 32-35 and 40-50 are currently under consideration.

Election/Restriction

Group I, claim(s) 1-2, 17-25, 32-35 and 40-50, drawn to a method for alimentary nutrition or treating hyperglycemia or hyperglycemic states.

Group II, claim(s) 26, 28-31 and 36-39 drawn to a composition comprising source of nutrients and insulinotropic peptide.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the "special technical feature" e.g. a composition comprising a CHO nutrient source and insulinotropic peptide, fails to define a contribution over the prior art since such compositions are available in the prior art. See E.g. Chen et al., U.S. Pat. No. 5,512,549 at col. 15-16 (Example 8) teaching glucose and insulinotropic peptide administered enterally, separately, or in combination; and Habener, U.S. Pat. No. 5,118,666 at bottom of col. 7 to top of col. 8 teaching compositions comprising insulinotropic peptides and several different sources of indirect/direct CHO nutrition.

Art Unit: 1627

1. Applicant's election with traverse of Group I (claims 1-2 and 17-25) and the species GLP-1 and glucose in Paper No. 12 is acknowledged. The traversal is on the ground(s) that there is no extra search burden to search the compound claims of Group II. This is not found persuasive because there is no special technical feature that links the compounds to the meths and as such the search of the composition claims are not limited to a particular use and thus would encompass additional and separately burdensome search.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 26, 28-31 and 36-39 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention..

Claim Objections

~~3.~~ Claims 49-50 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 2 is drawn to carbohydrate nutrients; neither pyruvate of claim 49 or lactate of claim 50 are carbohydrates.

Art Unit: 1627

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 21 and 47-48 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

? In claim 21, there is no support for the "range of 1 pmol/L to 1 nmol/l of blood plasma" presently claimed. *INJECTION ONLY*

✓ In claims 47-48, there is no support for "a derivative of said carbohydrates(nutrients)".

A response to this rejection must include cancellation of the new matter.

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1627

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

7. Claims 1-2, 17-19, 21-25, 32-35 and 40-48 are rejected under 35 U.S.C. 102(b) as being anticipated by Habener, U.S. Pat. No. 5,118,666 (6/92)

Habener '666 discloses the use of compositions comprising one or more GLP1 and derivative compounds (e.g. see col. 5-6) parenterally (e.g. iv, im, subcut: see e.g. col. 7, lines 60-70) in dosages (e.g. see col. 7, lines 65-70 and top of col 8) within the scope of the presently claimed invention to treat diabetes in view of the "insulinotropic" activity (e.g. see col. 4, lines 30-40) of these peptides. Parenteral formulation include various minerals in aqueous solution with the GLP1 peptides or conjugated thereto including lactose (a carbohydrate which is a "combination of hexoses" which include the combination of glucose and galactose); polyamino acids (e.g. amino acids or combination thereof); liposomes (e.g. combination of lipids) (e.g. see bottom of col. 7 and col. 8 ; as well as a perfusate which comprises GLP-1 (and its derivative) and glucose which achieves "plateau" insulin sustained release (e.g. see Example 9).

8. Claims 1-2, 17-19, 21-25, 32-35 and 40-48 are rejected under 35 U.S.C. 102(e) as being anticipated by Habener, U.S. Pat. No. 5,614,492 (3/97: filed 9/91 or earlier).

Habener "492 disclose the use of GLP 1 and its derivatives (e.g. col. 7) to treat both diabetes and hyperglycemia (e.g. see col. 6, lines 1-10) due to the peptide's "insulinotropic" activity (e.g. see col. 5; line 60-70). "Parenteral administration" of GLP 1 and its derivatives in

Art Unit: 1627

pharmaceutical compositions comprising carbohydrates (e.g. lactose), polyamino acids: controlled release formulations comprising lipid derivatives (e.g. liposomes) e.g. see bottom of col. 9 to top of col. 10) as well as conjugates thereof (e.g. see col. 10, lines 13-26) anticipate the presently claimed invention. Further Example 11 (e.g. col. 21-28, especially "meal studies") disclose the administration of GLP-1 both during a meal (e.g. 50% CHO; 30% fat; 20% protein: see e.g. col. 22, lines 55-67) and postprandial to both NORMAL and non-diabetic patients with the successful control of plasma glucose levels. Accordingly, the parenteral administration of GLP-1 and its derivatives before/during/after meals that both contained and generated CHO (e.g. especially glucose) anticipates the presently claimed invention. See also patent claims which additionally disclose the treatment of both diabetes and hyperglycemia utilizing GLP-1 containing compositions.

Claim Rejections - 35 USC § 103

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor

Art Unit: 1627

and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

10. Claims 1-2, 17-25, 32-35 and 40-50 are rejected under 35 U.S.C. 103(a) as being unpatentable over the Specification disclosure as to the state of the prior art in view of Habener, U.S. Pat. No. 5,614,492 (3/97: filed 9/91 or earlier) and/or Eng US Pat. No. 5,424,286 (6/95).

The specification on pages 1-2 and page 10, lines 15 describes the state of the prior art regarding the necessity for providing parenteral nutrition to patients having “disturbed glucose metabolism” (e.g. surgery patients, shock etc) as well as to malnourished patients while overcoming the hyperglycemia that accompanies parenteral nutrition. Coadministration of insulin with parenteral nutrition in order to overcome the hyperglycemia problem has its drawbacks (e.g. see page 1, lines 13-25).

The State of the Prior Art as described in the specification differs from the presently claimed invention which incorporates the use of “insulinotropic peptides” (e.g. GLP-1 and its derivatives) in parenteral nutrition compositions which comprise nutrients (e.g. glucose or glucose generating compounds) for alimentary nutrition or to treat hyperglycemic states.

However, both the Habener and Eng Patent references teach the “insulinotropic” nature of GLP-1 and related peptides e.g. the ability of these peptides to endogenously generate insulin and thus combat hyperglycemia. Additionally, the prior/sequential and co-administration of these “insulinotropic” peptides with a meal containing nutrients (e.g. which include glucose or generate

Art Unit: 1627

glucose) and the peptides concomitant ability to obtain normalized glucose levels is both disclosed and suggested by the Habener and/or Eng patents (e.g. see Habener, Example 11, col. 21-28 and patent claims addressing treatment of hyperglycemia; e.g. see Eng at col. 1, lines 49-67 disclosing lowering of meal-related glucose levels by parenteral administration of GLP-1 and GLIP which effect was also found with other “insulinotropic” peptides (e.g. extendins) alone or in combination (including sequential) with GLP-1 (e.g. see Eng col. 2, lines 35-40; col. 5, lines 14-20; Example 2 (col. 6-7); Example 5 relating to diabetics; and patent claims 5-6.

The determination of optimal amounts of “insulinotropic” peptides and/or nutrients taken sequentially or in combination is well within the skill of the art as well as the determination of optimal delivery formulations (e.g. tablets, pills, delayed release etc.) and time of delivery (e.g. coadministered, sequential etc.).

One of ordinary skill in the art would be motivated to substitute the “insulinotropic” peptides disclosed by the Eng or Habener references for insulin in “parenteral” formulations as disclosed in the Specification, due to the problematic use of insulin as discussed in the specification and in view of the ability of “insulinotropic peptides” to endogenously produce insulin as taught by the Eng and/or Habener references.

Accordingly, the incorporation of “insulinotropic” peptides (e.g. GLP-1 or its derivatives) into parenteral formulations containing “nutrients” to treat diabetics, non-diabetics (e.g. hyperglycemia) or malnourished individuals would have been obvious to one of ordinary skill in the art at the time of applicant’s invention in view of the Habener and/or Eng references which

Art Unit: 1627

demonstrate that administration of these peptides to obtain normalized glucose levels; regardless of the cause of hyperglycemia (meal/diabetes/hyperglycemia etc.).

General information regarding further correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Celsa whose telephone number is (703) 305-7556.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat (art unit 1627), can be reached at (703)308-0570.

Any inquiry of a general nature, or relating to the status of this application, should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Bennett Celsa (art unit 1627)

May 30, 2000

BENNETT CELSA
PRIMARY EXAMINER
